PipelineReview.com - All Products

Show Cart

All Products

Results 1 - 20 of 207

Sep 2023 c-Met-Targeted Antibody Therapy Pipeline Review

Sep 2023 PSMA-Targeted Therapy Pipeline Review

Sep 2023 Mesothelin-Targeted Immunotherapy Pipeline Review

Sep 2023 CCR8-Targeted Antibody Immunotherapy Pipeline Review

Aug 2023 CD40 Agonists & CD40/L Antagonists Pipeline Review

Aug 2023 Fibroblast Activation Protein (FAP) Targeted Therapy & Companion Diagnostic Pipeline Review

Aug 2023 Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

Aug 2023 IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

Aug 2023 Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

Jul 2023 Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review

Jul 2023 Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Jul 2023 Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

Jul 2023 Adalimumab (Humira) Biosimilars Pipeline Review

Jun 2023 Ranibizumab (Lucentis) Biosimilars Pipeline Review

Jun 2023 Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

Jun 2023 Aflibercept (Eylea) Biosimilars Pipeline Review

Jun 2023 Ustekinumab (Stelara) Biosimilars Pipeline Review

Jun 2023 TSLP Pipeline Review

Mar 2023 2022 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Feb 2023 CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

Shopping cart

Cart empty

Latest report

c-Met-Targeted Antibody Therapy Pipeline Review

Featured Products

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

CAR-M Industry Landscape Analysis: Chimeric Antigen Receptor-Macrophage (CAR-M) Stakeholders, Technologies, Pipeline, Partnering and Financing

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Latest Target Pipeline

CD40 Agonists & CD40/L Antagonists Pipeline Review

La Merie Biologics

FREE Weekly News Bulletin

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing